---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017328"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:27:45.894957+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity reports Q3 CyPath® Lung test sales up 95% QoQ, 97% YTD

## Summary
- CyPath® Lung test sales in Q3 2025 increased 95% over Q2 2025; nine-month sales up 97% vs same period 2024.
- Growth driven by adoption at Veterans’ hospitals and market expansion in the mid-Atlantic region.
- New patients using CyPath® Lung rose 77% in Q3; patient compliance for at-home sample collection improved.

## SEC filing metadata
- accession: 0001493152-25-017328
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225017328/0001493152-25-017328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225017328/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017328
- JSON: https://secwatch.observer/filing/0001493152-25-017328.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.